Jefferies analyst Andrew Tsai raised the firm’s price target on Alto Neuroscience (ANRO) to $25 from $15 and keeps a Buy rating on the shares. Investor confidence in Alto’s precision psychiatry ...

Thank you, everyone, for tuning in. I'm Andrew Tsai, Senior biotech analyst at Jefferies, and it's my pleasure to have the Lexicon team with me today. Sitting to the direct right of me is Craig ...

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

All right. We're going to get started with our next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. And it's my pleasure to have Marcio Souza, joining me today, CEO of Praxis. Welcome, ...